In this article, we review the current French price reimbursement scheme and how this scheme is affected by a new decree published in 1993, or will be affected by this decision already announced but not yet implemented. France has been perceived as a pioneering country regarding the attitude of the Health Authority towards pharmacoeconomics. Here, we describe the present status afforded such studies in the price reimbursement scheme. Finally, we discuss the possible impact of the national agreement between physicians and statutory Health Funds on the pharmaceutical industry in France.